Global Pathogen Safety, Baxter AG, A Takeda Company, Vienna, Austria.
Global Manufacturing Sciences, Baxter AG, A Takeda Company, Vienna, Austria.
Transfusion. 2021 Apr;61(4):1141-1147. doi: 10.1111/trf.16291. Epub 2021 Feb 22.
Coronavirus disease 2019 (COVID-19) convalescent individuals carry antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that, through a plasma donation, can be used as a potential therapeutic either in direct transfusion or for the manufacture of hyperimmune globulin (HIG). The success of such interventions depends on the antibody potency in such plasma donations, but little information on the collection of potent units is currently available.
A total of 8749 plasma units, collected from April until September 2020 from first-time U.S. COVID-19 convalescent plasma donors, were characterized for SARS-CoV-2 immunoglobulin G (IgG) antibodies by Abbott chemiluminescent microparticle immunoassay (CMIA). The period between COVID-19 onset until donation and donor age, ethnicity, sex, and COVID-19 severity were evaluated against the obtained signal (index S/C).
A marked decrease in mean index S/C was seen over the plasma collection period surveyed, which was significantly correlated to decreases in mean plasma donor age (p < .0001; R = .726) and percentage of donations obtained from COVID-19 convalescent patients who had been hospitalized (p = .001; R = .4426). The highest titer plasma units were obtained soon after convalescence from COVID-19 patients who required hospitalization, from advanced age donors, and from Black/African/Hispanic American versus White/Caucasian ethnicities, whereas there was no effect of donor sex on the values obtained with the Abbott CMIA.
Since the onset of the pandemic, the average SARS-CoV-2 IgG values of first-time U.S. COVID-19 convalescent plasma donations have significantly dropped, mainly due to donations from progressively younger aged donors who tend to experience less severe COVID-19.
2019 年冠状病毒病（COVID-19）康复者携带针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的抗体，这些抗体可通过血浆捐献用于潜在治疗，直接输注或用于生产高免疫球蛋白（HIG）。此类干预措施的成功取决于此类血浆捐献中的抗体效价，但目前有关有效单位采集的信息很少。
共对 8749 份血浆单位进行了分析，这些血浆单位于 2020 年 4 月至 9 月期间首次从美国 COVID-19 康复期血浆供体中采集，通过 Abbott 化学发光微粒子免疫分析（CMIA）对 SARS-CoV-2 免疫球蛋白 G（IgG）抗体进行了特征分析。评估了 COVID-19 发病至捐赠之间的时间间隔、供体年龄、种族、性别和 COVID-19 严重程度与获得的信号（指数 S/C）之间的关系。
在所调查的血浆采集期间，平均指数 S/C 明显下降，且与平均血浆供体年龄的下降显著相关（p < 0.0001；R =.726），与从住院 COVID-19 康复患者获得的献血百分比呈正相关（p =.001；R =.4426）。从 COVID-19 住院患者康复后不久、年龄较大的供体以及黑/非裔/西班牙裔美国人中获得的最高滴度血浆单位，与白人/高加索人相比，而捐赠者性别对 Abbott CMIA 获得的数值没有影响。
自大流行开始以来，首次来自美国 COVID-19 康复期血浆捐献的 SARS-CoV-2 IgG 值明显下降，主要是由于来自年龄较大的供体的捐献量增加，而这些供体的 COVID-19 病情往往较轻。
